A Serendipitous Preoperative Trial of Combined Ipilimumab Plus Nivolumab for Localized Prostate Cancer

Jeroen van Dorp; Maurits L. van Montfoort; Nick van Dijk; Ingrid Hofland; Jeantine M. de Feijter; Andries M. Bergman; Kees Hendricksen; Henk G. van der Poel; Bas W. G. van Rhijn; Michiel S. van der Heijden

doi:https://doi.org/10.1016/j.clgc.2021.12.004

A Serendipitous Preoperative Trial of Combined Ipilimumab Plus Nivolumab for Localized Prostate Cancer

Jeroen van Dorp, Maurits L. van Montfoort, Nick van Dijk, Ingrid Hofland, Jeantine M. de Feijter, Andries M. Bergman, Kees Hendricksen, Henk G. van der Poel, Bas W. G. van Rhijn, Michiel S. van der Heijden

Doctoral School

Research output: Contribution to journal › Article › Academic › peer-review

1 Citation (Scopus)

Abstract

• Incidental prostate cancer was found in cystoprostatectomy specimens in 9 out of 16 patients treated in the NABUCCO trial. • This was not statistically different from incidental prostate cancer observed after cystoprostatectomy in a control cohort. • Based on histopathological analysis and immunohistochemistry, we found no evidence for response to ipilimumab and nivolumab in incidental prostate cancer in the NABUCCO trial.

Original language	English
Pages (from-to)	e173-e179
Journal	Clinical genitourinary cancer
Volume	20
Issue number	2
DOIs	https://doi.org/10.1016/j.clgc.2021.12.004
Publication status	Published - 1 Apr 2022

Keywords

Immune checkpoint inhibitors
Neo-adjuvant therapy
Prostate cancer
Surgery

Access to Document

https://doi.org/10.1016/j.clgc.2021.12.004

Cite this

van Dorp, J., van Montfoort, M. L., van Dijk, N., Hofland, I., de Feijter, J. M., Bergman, A. M., Hendricksen, K., van der Poel, H. G., van Rhijn, B. W. G., & van der Heijden, M. S. (2022). A Serendipitous Preoperative Trial of Combined Ipilimumab Plus Nivolumab for Localized Prostate Cancer. Clinical genitourinary cancer, 20(2), e173-e179. https://doi.org/10.1016/j.clgc.2021.12.004

@article{2e02671eeb4e4357a14b87439ef19525,

title = "A Serendipitous Preoperative Trial of Combined Ipilimumab Plus Nivolumab for Localized Prostate Cancer",

abstract = "• Incidental prostate cancer was found in cystoprostatectomy specimens in 9 out of 16 patients treated in the NABUCCO trial. • This was not statistically different from incidental prostate cancer observed after cystoprostatectomy in a control cohort. • Based on histopathological analysis and immunohistochemistry, we found no evidence for response to ipilimumab and nivolumab in incidental prostate cancer in the NABUCCO trial.",

keywords = "Immune checkpoint inhibitors, Neo-adjuvant therapy, Prostate cancer, Surgery",

author = "{van Dorp}, Jeroen and {van Montfoort}, {Maurits L.} and {van Dijk}, Nick and Ingrid Hofland and {de Feijter}, {Jeantine M.} and Bergman, {Andries M.} and Kees Hendricksen and {van der Poel}, {Henk G.} and {van Rhijn}, {Bas W. G.} and {van der Heijden}, {Michiel S.}",

note = "Funding Information: We would like to acknowledge all clinical staff involved in the NABUCCO trial, the core facility molecular pathology and biobanking for support, the pathology department for analysis of multiplex immunofluorescence stainings, and E. Bekers for critically reviewing all selected tissue slides, all at the Netherlands Cancer Institute. Bristol-Myers Squibb provided the study drugs and funding for the NABUCCO trial. Publisher Copyright: {\textcopyright} 2021",

year = "2022",

month = apr,

day = "1",

doi = "https://doi.org/10.1016/j.clgc.2021.12.004",

language = "English",

volume = "20",

pages = "e173--e179",

journal = "Clinical genitourinary cancer",

issn = "1558-7673",

publisher = "Elsevier",

number = "2",

}

van Dorp, J, van Montfoort, ML, van Dijk, N, Hofland, I, de Feijter, JM, Bergman, AM, Hendricksen, K, van der Poel, HG, van Rhijn, BWG & van der Heijden, MS 2022, 'A Serendipitous Preoperative Trial of Combined Ipilimumab Plus Nivolumab for Localized Prostate Cancer', Clinical genitourinary cancer, vol. 20, no. 2, pp. e173-e179. https://doi.org/10.1016/j.clgc.2021.12.004

TY - JOUR

T1 - A Serendipitous Preoperative Trial of Combined Ipilimumab Plus Nivolumab for Localized Prostate Cancer

AU - van Dorp, Jeroen

AU - van Montfoort, Maurits L.

AU - van Dijk, Nick

AU - Hofland, Ingrid

AU - de Feijter, Jeantine M.

AU - Bergman, Andries M.

AU - Hendricksen, Kees

AU - van der Poel, Henk G.

AU - van Rhijn, Bas W. G.

AU - van der Heijden, Michiel S.

N1 - Funding Information: We would like to acknowledge all clinical staff involved in the NABUCCO trial, the core facility molecular pathology and biobanking for support, the pathology department for analysis of multiplex immunofluorescence stainings, and E. Bekers for critically reviewing all selected tissue slides, all at the Netherlands Cancer Institute. Bristol-Myers Squibb provided the study drugs and funding for the NABUCCO trial. Publisher Copyright: © 2021

PY - 2022/4/1

Y1 - 2022/4/1

N2 - • Incidental prostate cancer was found in cystoprostatectomy specimens in 9 out of 16 patients treated in the NABUCCO trial. • This was not statistically different from incidental prostate cancer observed after cystoprostatectomy in a control cohort. • Based on histopathological analysis and immunohistochemistry, we found no evidence for response to ipilimumab and nivolumab in incidental prostate cancer in the NABUCCO trial.

AB - • Incidental prostate cancer was found in cystoprostatectomy specimens in 9 out of 16 patients treated in the NABUCCO trial. • This was not statistically different from incidental prostate cancer observed after cystoprostatectomy in a control cohort. • Based on histopathological analysis and immunohistochemistry, we found no evidence for response to ipilimumab and nivolumab in incidental prostate cancer in the NABUCCO trial.

KW - Immune checkpoint inhibitors

KW - Neo-adjuvant therapy

KW - Prostate cancer

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=85122520328&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.clgc.2021.12.004

DO - https://doi.org/10.1016/j.clgc.2021.12.004

M3 - Article

C2 - 35016887

SN - 1558-7673

VL - 20

SP - e173-e179

JO - Clinical genitourinary cancer

JF - Clinical genitourinary cancer

IS - 2

ER -

A Serendipitous Preoperative Trial of Combined Ipilimumab Plus Nivolumab for Localized Prostate Cancer

Abstract

Keywords

Access to Document

Other files and links

Cite this